Stocklytics Platform
Asset logo for symbol YMAB
Y-mAbs Therapeutics
YMAB57
$14.04arrow_drop_down0.77%-$0.10
Asset logo for symbol YMAB
YMAB57

$14.04

arrow_drop_down0.77%
Key Stats
Open$14.16
Prev. Close$14.16
EPS-0.56
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range13.49
14.16
52 Week Range4.69
20.90
Ratios
EPS-0.56
Fundamentals
Payout Ratio-
Industry average yield2.89%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

YMAB-
US Healthcare Sector-
US Market-
check_circle

YMAB / Market

YMAB exceeded the US Market which returned 1.73% over the last twenty four hours.
check_circle

YMAB / Healthcare Sector

YMAB exceeded the US Healthcare sector which returned 1.88% over the last twenty four hours.

Y-mAbs Therapeutics (YMAB) Statistics

Y-mAbs Therapeutics Inc (YMAB) is a biopharmaceutical company that focuses on the development and commercialization of novel antibody-based therapies for the treatment of cancer. The company's primary goal is to improve the lives of patients with cancer by providing effective and safe treatment options. As of [insert current date], YMAB stock statistics reveal that the company's stock is performing well in the market. It is important for investors to analyze the valuation metrics of YMAB to determine its potential for growth. The valuation metrics provide insights into the company's financial health and its potential for creating value for shareholders.
When looking at the fundamentals of YMAB, it is evident that the company has strong revenue per share. This metric indicates the amount of revenue generated by each outstanding share of the company's stock. A high revenue per share suggests that the company is generating significant income and has the potential to deliver positive returns for investors. Another important metric to consider is the Enterprise to EBITDA ratio, which measures the company's ability to generate earnings before interest, taxes, depreciation, and amortization relative to its enterprise value. A low Enterprise to EBITDA ratio indicates that the company's stock may be undervalued and could present a buying opportunity for investors.
add Y-mAbs Therapeutics  to watchlist

Keep an eye on Y-mAbs Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Y-mAbs Therapeutics (YMAB) stock's performance compared to its sector and the market over the past year?

Over the past year, Y-mAbs Therapeutics (YMAB) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 32.11%, Y-mAbs Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 67.22%, it has fallen short of the market average. This comparison highlights Y-mAbs Therapeutics 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Y-mAbs Therapeutics (YMAB) stock?

The PE ratio for Y-mAbs Therapeutics (YMAB) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Y-mAbs Therapeutics (YMAB) stock?

The Earnings Per Share (EPS) for Y-mAbs Therapeutics (YMAB), calculated on a diluted basis, is -$0.56. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Y-mAbs Therapeutics (YMAB) stock?

The operating margin for Y-mAbs Therapeutics (YMAB) is -42.94%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Y-mAbs Therapeutics (YMAB) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Y-mAbs Therapeutics (YMAB) is -$27M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Y-mAbs Therapeutics (YMAB) have?

Y-mAbs Therapeutics (YMAB) has a total debt of $1.27M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$76.53M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media